In addition to the core signaling pathways identified in these studies, Bredel et al. reported the frequent heterozygous deletion of the NFkB inhibitor alpha (NFKBIA) gene occurring in approximately 25% of glioblastoma patients [11]. This evidence concerns the gene NFKBIA and glioblastoma.